Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 2:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 7,074 matching trials from the live ClinicalTrials.gov search.
Conditions
Generalized Anxiety Disorder
Interventions
PF-06372865.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Cerritos, California • Encino, California • Imperial, California + 41 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Healthy
Interventions
STSA-1005 injection, Placebo
Drug
Lead sponsor
Staidson Biopharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Healthy
Interventions
AZD9742, Placebo to match AZD9742
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Not applicable Interventional Accepts healthy volunteers

Antioxidant Responses to Exercise and Cherry Consumption

NCT03522779
Conditions
Dietary Modification
Interventions
Tart cherry Juice, High-fat meal, Exercise
Dietary Supplement · Other
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Athens, Georgia
Conditions
Obesity
Interventions
CX11, Placebo
Drug · Other
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Inglewood, California • San Diego, California + 13 more
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Corticosteroid
Drug · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more
Conditions
Atopic Dermatitis
Interventions
TRIV-573, Placebo
Drug
Lead sponsor
Triveni Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Fountain Valley, California • Los Angeles, California • Boca Raton, Florida + 8 more
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction

NCT00487578
Conditions
Post Traumatic Headache
Interventions
naratriptan HCl
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
3
States / cities
Springfield, Missouri • Charlotte, North Carolina • Dallas, Texas
Conditions
Depressive Disorder, Major
Interventions
BI 1569912, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Tucson, Arizona • Oceanside, California • Orange, California + 17 more
Conditions
Asthma
Interventions
AMG 827, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 19 more
Conditions
NASH
Interventions
Pegozafermin, Placebo
Drug · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more
Completed Phase 1Phase 2 Interventional Results available

Effect of CT1812 Treatment on Brain Synaptic Density

NCT03493282
Conditions
Alzheimer Disease
Interventions
Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
Ipilimumab, Placebo, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 24 more
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
Dolutegravir, Atripla, Abacavir/Lamivudine, Abacavir/Lamivudine Placebo, Dolutegravir placebo, Atripla placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
55
States / cities
Hobson City, Alabama • Little Rock, Arkansas • Bakersfield, California + 42 more
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Brensocatib 10 mg, Brensocatib 25 mg, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Peoria, Arizona • Newport Beach, California + 30 more
Conditions
Ulcerative Colitis
Interventions
HMPL-004 1800 mg/day, Placebo, HMPL-004 2400 mg/day
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Agawam, Massachusetts
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Conditions
Postoperative Delirium, PD, Postoperative Cognitive Dysfunction, POCD
Interventions
Precedex (Dexmedetomidine), Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Cocaine Dependence
Interventions
oxytocin, saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Woodsmoke Particulate + Prednisone

NCT03861390
Conditions
Airway Inflammation
Interventions
60 mg Prednisone, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Active, not recruiting Phase 3 Interventional

Brain Activation and Satiety in Children 2

NCT04520490
Conditions
Childhood Obesity
Interventions
Family Based Behavioral Treatment, Exenatide 2 mg [Bydureon], Placebo
Behavioral · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
10 Years to 12 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Depressive Disorder, Anhedonia
Interventions
Ezogabine, Placebos
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Schizophrenia
Interventions
ACP-104, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Dallas, Texas